Lebwohl MG - Search Results

1

Brodalumab: Six-Year US Pharmacovigilance Report.

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL Jr, Mangin GD, Jacobson AA. Lebwohl MG, et al. Dermatol Ther (Heidelb). 2024 Nov 26. doi: 10.1007/s13555-024-01304-y. Online ahead of print. Dermatol Ther (Heidelb). 2024. PMID: 39589679

2

Two-Year US Pharmacovigilance Report on Brodalumab.

Lebwohl M, Leonardi C, Wu JJ, Armstrong A, Rawnsley N, Merchant M, Alexander B, Jacobson A. Lebwohl M, et al. Dermatol Ther (Heidelb). 2021 Feb;11(1):173-180. doi: 10.1007/s13555-020-00472-x. Epub 2020 Dec 18. Dermatol Ther (Heidelb). 2021. PMID: 33337520 Free PMC article.

3

Three-year U.S. pharmacovigilance report of brodalumab.

Lebwohl M, Leonardi C, Armstrong A, Rawnsley N, Alexander B, Goehring E Jr, Kerdel F, Jacobson A. Lebwohl M, et al. Dermatol Ther. 2021 Nov;34(6):e15105. doi: 10.1111/dth.15105. Epub 2021 Sep 5. Dermatol Ther. 2021. PMID: 34418244 Free PMC article.

4

Brodalumab: 5-Year US Pharmacovigilance Report.

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Martin GM, Rawnsley NN, Goehring EL Jr, Jacobson AA. Lebwohl MG, et al. Dermatol Ther (Heidelb). 2024 May;14(5):1349-1357. doi: 10.1007/s13555-024-01162-8. Epub 2024 May 9. Dermatol Ther (Heidelb). 2024. PMID: 38724839 Free PMC article.

5

Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses.

Lebwohl MG, Armstrong AW, Alexis AF, Lain EL, Jacobson AA. Lebwohl MG, et al. Dermatol Ther (Heidelb). 2024 Oct;14(10):2709-2726. doi: 10.1007/s13555-024-01264-3. Epub 2024 Sep 12. Dermatol Ther (Heidelb). 2024. PMID: 39264399 Free PMC article. Review.

6

Duration of remission of psoriasis therapies.

Koo J, Lebwohl M. Koo J, et al. J Am Acad Dermatol. 1999 Jul;41(1):51-9. doi: 10.1016/s0190-9622(99)70406-8. J Am Acad Dermatol. 1999. PMID: 10411411 Review.

7

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.

Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. Lebwohl MG, et al. Am J Clin Dermatol. 2016 Feb;17(1):87-97. doi: 10.1007/s40257-015-0169-x. Am J Clin Dermatol. 2016. PMID: 26718712 Free PMC article.

8

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.

Langley RG, Armstrong AW, Lebwohl MG, Blauvelt A, Hsu S, Tyring S, Rastogi S, Pillai R, Israel R. Langley RG, et al. Among authors: lebwohl mg. Br J Dermatol. 2019 Feb;180(2):306-314. doi: 10.1111/bjd.17318. Epub 2018 Dec 27. Br J Dermatol. 2019. PMID: 30328108

9

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.

Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA. Puig L, et al. J Am Acad Dermatol. 2020 Feb;82(2):352-359. doi: 10.1016/j.jaad.2019.05.095. Epub 2019 Jun 5. J Am Acad Dermatol. 2020. PMID: 31175909 Free article. Clinical Trial.

10

Immunogenicity and skin clearance recapture in clinical studies of brodalumab.

Bagel J, Lebwohl M, Israel RJ, Jacobson A. Bagel J, et al. J Am Acad Dermatol. 2020 Feb;82(2):344-351. doi: 10.1016/j.jaad.2019.05.094. Epub 2019 Jun 5. J Am Acad Dermatol. 2020. PMID: 31175910 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

623 results

Search Page

Filters